Genscript Biotech: Associate Legend Biotech Posts US$657.00 Million Q2 Sales for CARVYKTI®

Bulletin Express07-15 20:41

Genscript Biotech Corporation (01548.HK) disclosed that its Nasdaq-listed associate, Legend Biotech Corporation, has reported preliminary net trade sales of approximately US$657.00 million for CARVYKTI® (ciltacabtagene autoleucel) in the quarter ended 30 June 2026. The data were included in Legend’s Form 6-K filed with the United States Securities and Exchange Commission on 15 July 2026 (New York time).

CARVYKTI® is commercialised under a Collaboration and License Agreement signed on 21 December 2017 between Legend Biotech and Janssen Biotech, Inc. The reported sales figure is based on information supplied by Janssen; neither Legend Biotech nor Genscript Biotech has independently verified the number.

This marks the second consecutive quarter in which Legend has disclosed preliminary sales for CARVYKTI®, following the company’s earlier update for the three months ended 31 March 2026. No comparative figures for that period were included in the latest filing.

The announcement reiterates standard forward-looking statements and risk disclosures, highlighting potential variability in future results due to clinical, regulatory, competitive and intellectual-property factors. Shareholders and potential investors are advised to consider these risks and to exercise caution when dealing in Genscript Biotech’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154933815?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 20:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154933815","market":"us","top_or_hot":-1,"title":"Genscript Biotech: Associate Legend Biotech Posts US$657.00 Million Q2 Sales for CARVYKTI®","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation (01548.HK) disclosed that its Nasdaq-listed associate, Legend Biotech Corporation, has reported preliminary net trade sales of approximately US$657.00 million for CARVYKTI® (ciltacabtagene autoleucel) in the quarter ended 30 June 2026. The data were included in Legend’s Form 6-K filed with the United States Securities and Exchange Commission on 15 July 2026 (New York time).</p>\n<p>CARVYKTI® is commercialised under a Collaboration and License Agreement signed on 21 December 2017 between Legend Biotech and Janssen Biotech, Inc. The reported sales figure is based on information supplied by Janssen; neither Legend Biotech nor Genscript Biotech has independently verified the number.</p>\n<p>This marks the second consecutive quarter in which Legend has disclosed preliminary sales for CARVYKTI®, following the company’s earlier update for the three months ended 31 March 2026. No comparative figures for that period were included in the latest filing.</p>\n<p>The announcement reiterates standard forward-looking statements and risk disclosures, highlighting potential variability in future results due to clinical, regulatory, competitive and intellectual-property factors. Shareholders and potential investors are advised to consider these risks and to exercise caution when dealing in Genscript Biotech’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript Biotech: Associate Legend Biotech Posts US$657.00 Million Q2 Sales for CARVYKTI®</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript Biotech: Associate Legend Biotech Posts US$657.00 Million Q2 Sales for CARVYKTI®\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-15 20:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech Corporation (01548.HK) disclosed that its Nasdaq-listed associate, Legend Biotech Corporation, has reported preliminary net trade sales of approximately US$657.00 million for CARVYKTI® (ciltacabtagene autoleucel) in the quarter ended 30 June 2026. The data were included in Legend’s Form 6-K filed with the United States Securities and Exchange Commission on 15 July 2026 (New York time).</p>\n<p>CARVYKTI® is commercialised under a Collaboration and License Agreement signed on 21 December 2017 between Legend Biotech and Janssen Biotech, Inc. The reported sales figure is based on information supplied by Janssen; neither Legend Biotech nor Genscript Biotech has independently verified the number.</p>\n<p>This marks the second consecutive quarter in which Legend has disclosed preliminary sales for CARVYKTI®, following the company’s earlier update for the three months ended 31 March 2026. No comparative figures for that period were included in the latest filing.</p>\n<p>The announcement reiterates standard forward-looking statements and risk disclosures, highlighting potential variability in future results due to clinical, regulatory, competitive and intellectual-property factors. Shareholders and potential investors are advised to consider these risks and to exercise caution when dealing in Genscript Biotech’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1154933815","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154933815","pubTimestamp":1784119284,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation (01548.HK) disclosed that its Nasdaq-listed associate, Legend Biotech Corporation, has reported preliminary net trade sales of approximately US$657.00 million for...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞生物：联想生物公布 CARVYKTI 第二季度销售额达 6.577 亿美元®","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation (01548.HK) disclosed that its Nasdaq-listed associate, Legend Biotech Corporation, has reported preliminary net trade sales of approximately US$657.00 million for CARVYKTI® (ciltacabtagene autoleucel) in the quarter ended 30 June 2026. The data were included in Legend’s Form 6-K filed with the United States Securities and Exchange Commission on 15 July 2026 (New York time).\nCARVYKTI® is commercialised under a Collaboration and License Agreement signed on 21 December 2017 between Legend Biotech and Janssen Biotech, Inc. The reported sales figure is based on information supplied by Janssen; neither Legend Biotech nor Genscript Biotech has independently verified the number.\nThis marks the second consecutive quarter in which Legend has disclosed preliminary sales for CARVYKTI®, following the company’s earlier update for the three months ended 31 March 2026. No comparative figures for that period were included in the latest filing.\nThe announcement reiterates standard forward-looking statements and risk disclosures, highlighting potential variability in future results due to clinical, regulatory, competitive and intellectual-property factors. Shareholders and potential investors are advised to consider these risks and to exercise caution when dealing in Genscript Biotech’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154933815","isCrawlerRequest":true}